Tenet Healthcare Corporation (NYSE:THC) Receives $244.84 Consensus Target Price from Brokerages

Tenet Healthcare Corporation (NYSE:THC) has received a consensus rating of “Moderate Buy” from the twenty ratings firms that are presently covering the stock, MarketBeat.com reports. Three investment analysts have rated the stock with a hold recommendation and seventeen have assigned a buy recommendation to the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $268.50.

THC has been the subject of several recent analyst reports. Truist Financial upped their target price on Tenet Healthcare from $270.00 to $290.00 and gave the company a “buy” rating in a report on Tuesday. The Goldman Sachs Group reissued a “buy” rating and issued a $305.00 price objective on shares of Tenet Healthcare in a research report on Tuesday. UBS Group raised their target price on Tenet Healthcare from $288.00 to $308.00 and gave the company a “buy” rating in a research report on Monday. Royal Bank Of Canada boosted their price target on shares of Tenet Healthcare from $236.00 to $283.00 and gave the stock an “outperform” rating in a report on Monday. Finally, Raymond James Financial set a $270.00 price objective on shares of Tenet Healthcare in a report on Monday.

Insider Activity at Tenet Healthcare

In other news, Director J Robert Kerrey sold 5,638 shares of the firm’s stock in a transaction that occurred on Thursday, May 28th. The shares were sold at an average price of $174.52, for a total transaction of $983,943.76. Following the completion of the sale, the director owned 16,804 shares in the company, valued at $2,932,634.08. This trade represents a 25.12% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Christopher S. Lynch sold 3,837 shares of the company’s stock in a transaction that occurred on Monday, July 27th. The shares were sold at an average price of $243.44, for a total value of $934,079.28. Following the completion of the transaction, the director owned 9,568 shares in the company, valued at approximately $2,329,233.92. The trade was a 28.62% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 23,353 shares of company stock worth $5,103,217. 0.97% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Tenet Healthcare

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in THC. Triumph Capital Management bought a new position in Tenet Healthcare during the third quarter worth about $25,000. Activest Wealth Management bought a new stake in shares of Tenet Healthcare in the fourth quarter valued at approximately $26,000. Elyxium Wealth LLC purchased a new stake in shares of Tenet Healthcare during the 4th quarter valued at approximately $29,000. Meeder Asset Management Inc. boosted its holdings in Tenet Healthcare by 146.2% in the 4th quarter. Meeder Asset Management Inc. now owns 192 shares of the company’s stock worth $38,000 after buying an additional 114 shares during the period. Finally, Canada Pension Plan Investment Board bought a new stake in Tenet Healthcare during the 2nd quarter valued at $35,000. 95.44% of the stock is currently owned by institutional investors.

Tenet Healthcare News Summary

Here are the key news stories impacting Tenet Healthcare this week:

• Positive Sentiment: Strong earnings underpin the rally: Tenet’s latest quarterly results showed EPS of $6.12, well above the $4.26 consensus estimate, while revenue of $6.04 billion also exceeded expectations. Revenue increased 6.8% year over year, and the company raised its 2026 outlook, reinforcing confidence in operating performance and cost discipline. Tenet Healthcare earnings and outlook
• Positive Sentiment: Analysts raised price targets: Truist lifted its target to $290 from $270 and maintained a “buy” rating. Guggenheim raised its target to $283 from $242 and also rated the shares “buy.” Baird increased its target to $280 from $210, although it retained a neutral rating. The revisions reflect improved earnings expectations following Tenet’s results. Analyst price-target updates
• Positive Sentiment: Growth and momentum remain favorable: Zacks highlighted THC as a potentially attractive growth, value and momentum stock based on earnings estimates, estimate revisions and recent price strength. Tenet’s shares recently reached a 52-week high, which may continue to draw momentum-focused investors. Zacks growth analysis
• Neutral Sentiment: Valuation and consensus outlook: THC trades at roughly 10 times earnings, while 17 analysts rate the stock “buy” and three rate it “hold.” The average price target is approximately $268.50, suggesting analysts remain constructive but that much of the near-term upside may already be reflected in the share price. Zacks value analysis
• Negative Sentiment: Insider selling creates an overhang: EVP Paola M. Arbour sold 10,878 shares for about $2.65 million, reducing her holdings by 37.14%. Director Christopher Lynch sold 3,837 shares valued at approximately $934,000, cutting his position by 28.62%. The sales may be personal transactions, but their size could weigh on sentiment after the recent run-up. Tenet Healthcare insider filing

Tenet Healthcare Stock Down 2.0%

THC opened at $257.37 on Thursday. Tenet Healthcare has a fifty-two week low of $155.02 and a fifty-two week high of $262.68. The firm has a market capitalization of $22.17 billion, a P/E ratio of 9.93, a PEG ratio of 1.02 and a beta of 1.27. The company’s 50-day moving average is $188.99 and its 200 day moving average is $198.60. The company has a debt-to-equity ratio of 2.00, a current ratio of 1.41 and a quick ratio of 1.35.

Tenet Healthcare (NYSE:THC) last issued its quarterly earnings data on Thursday, July 23rd. The company reported $6.12 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.26 by $1.86. Tenet Healthcare had a net margin of 10.27% and a return on equity of 26.76%. The business had revenue of $6.04 billion during the quarter, compared to the consensus estimate of $5.43 billion. During the same period in the prior year, the firm posted $4.02 EPS. The firm’s quarterly revenue was up 6.8% compared to the same quarter last year. Tenet Healthcare has set its FY 2026 guidance at 20.300-21.690 EPS. Research analysts expect that Tenet Healthcare will post 20.62 earnings per share for the current fiscal year.

Tenet Healthcare Company Profile

Tenet Healthcare Corporation (NYSE: THC) is a diversified American healthcare services company that owns and operates acute care hospitals and a broad range of outpatient facilities. Its portfolio includes general acute-care hospitals, specialty hospitals, ambulatory surgery centers, urgent care and diagnostic imaging centers, and other ancillary service locations. Tenet’s operations are oriented around delivering inpatient and outpatient clinical care across multiple medical specialties, with an emphasis on surgical services, emergency care, and advanced diagnostics.

In addition to facility-based care, Tenet provides integrated services designed to support clinical operations and improve patient access and care coordination.